Fingerprint
Dive into the research topics of 'Rituximab in primary membranous nephropathy: First-line therapy, why not?'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Rituximab in primary membranous nephropathy: First-line therapy, why not?
Paolo Cravedi, Giuseppe Remuzzi, Piero Ruggenenti
Research output: Contribution to journal › Article › peer-review